Evalueringen af risici kontra fordele skal foretages på individuel basis, hvor risikoen ved behandling med hydroxycarbamid opvejes mod et skift til et blodtransfusionsprogram.
The evaluation of the risk- benefit ratio should be made on an individual basis outweighing the respective risk of hydroxycarbamide therapy against the switch to a blood transfusion programme.